IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of...
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
About this item
Full title
Author / Creator
Mace, Thomas A , Shakya, Reena , Pitarresi, Jason R , Swanson, Benjamin , McQuinn, Christopher W , Loftus, Shannon , Nordquist, Emily , Cruz-Monserrate, Zobeida , Yu, Lianbo , Young, Gregory , Zhong, Xiaoling , Zimmers, Teresa A , Ostrowski, Michael C , Ludwig, Thomas , Bloomston, Mark , Bekaii-Saab, Tanios and Lesinski, Gregory B
Publisher
England: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
ObjectiveLimited efficacy of immune checkpoint inhibitors in pancreatic ductal adenocarcinoma (PDAC) has prompted investigation into combination therapy. We hypothesised that interleukin 6 (IL-6) blockade would modulate immunological features of PDAC and enhance the efficacy of anti-programmed death-1-ligand 1 (PD-L1) checkpoint inhibitor therapy.D...
Alternative Titles
Full title
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5406266
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5406266
Other Identifiers
ISSN
0017-5749
E-ISSN
1468-3288
DOI
10.1136/gutjnl-2016-311585
